Advice
following a full submission
lisdexamfetamine dimesylate (Elvanse Adult®) is accepted for use within NHS Scotland.
Indication under review: as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. Based on clinical judgment, patients should have ADHD of at least moderate severity.
Three phase III and two phase IV clinical studies in adults with ADHD demonstrated that lisdexamfetamine improves the symptoms of ADHD compared with placebo.
Download detailed advice200KB (PDF)
Medicine details
- Medicine name:
- lisdexamfetamine dimesylate (Elvanse Adult)
- SMC ID:
- 1079/15
- Indication:
- Indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.
- Pharmaceutical company
- Shire Pharmaceuticals
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 September 2015